ArticleACS applied bio materials2025
Potential of Nitric Oxide and Bacteriophages as Combined Antibacterial Agents to Counter Drug-Resistant Infections.
Article in ACS applied bio materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The ongoing threat of antimicrobial-resistant (AMR) bacteria and the growing population of AMR bacteria have inspired research into alternative antimicrobial agents. Previous studies have shown clinically relevant bactericidal effects of the molecule nitric oxide (NO). Not only has extensive research proven its antimicrobial effect, but bacteria have also been shown to be less likely to become resistant to NO. Numerous studies have also demonstrated that NO is compatible with commercially available antibiotic drugs, enhancing antimicrobial effects. However, these drugs are not always readily available or easily manufactured. This study proposes combining NO with naturally sourced antibacterial agents, namely bacteriophages. This combination of NO with bacteriophages in solution demonstrated an 82 ± 1.7% killing efficiency against its target pathogen,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.